Digoxin treatment in heart failure - Unveiling risk by cluster analysis of DIG data

Sameer Ather, Leif E. Peterson, Vijay G. Divakaran, Anita Deswal, Kumudha Ramasubbu, Irakli Giorgberidze, Alvin Blaustein, Xander H.T. Wehrens, Douglas L. Mann, Biykem Bozkurt

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Background: Digoxin has been shown to reduce heart failure (HF) hospitalizations with no overall effect on mortality in HF patients. We used cluster analysis to delineate the clinical characteristics of HF patients in whom digoxin therapy was associated with improved or worsened clinical outcomes. Methods: The Digitalis Investigation Group (DIG) database was partitioned into 20 clusters. Multivariate Cox regression analyses was used, to identify clusters in which digoxin was associated with either an increase (Mortality digHR > 1), decrease (Mortality digHR < 1), or no association with all cause mortality (Mortality digHR - NS); and separately, with an increase (HFA digHR > 1), decrease (HFA digHR < 1), or no association (HFA digHR - NS) with HF admissions (HFA). Results: We identified 938 patients in the Mortality digHR > 1 group, 6818 patients in the Mortality digHR - NS group, and none in Mortality digHR < 1 group. The Mortality digHR > 1 group had a higher prevalence of females, diabetes mellitus, hypertension, higher age, systolic blood pressure (SBP), heart rate and ejection fraction (EF), compared to the Mortality digHR - NS group. Similarly, 6325 patients clustered in the HFA digHR < 1 group, 1431 patients in the HFA digHR - NS group, and none in the HFA digHR > 1 group. The HFA digHR - NS group had a higher prevalence of females and hypertension, higher SBP, body mass index and EF; and lower prevalence of peripheral edema and third heart sound, compared with the HFA digHR < 1 group. Conclusion: Thus, the baseline characteristics of patients who did not have reduction in HF hospitalization or who had increased mortality were very similar and included females with hypertension, higher EF and higher SBP. Thus, use of digoxin in patients with this profile may need to be avoided.

Original languageEnglish
Pages (from-to)264-269
Number of pages6
JournalInternational Journal of Cardiology
Volume150
Issue number3
DOIs
StatePublished - Aug 4 2011
Externally publishedYes

Keywords

  • Cluster analysis
  • Digoxin
  • Heart failure

Fingerprint Dive into the research topics of 'Digoxin treatment in heart failure - Unveiling risk by cluster analysis of DIG data'. Together they form a unique fingerprint.

  • Cite this

    Ather, S., Peterson, L. E., Divakaran, V. G., Deswal, A., Ramasubbu, K., Giorgberidze, I., Blaustein, A., Wehrens, X. H. T., Mann, D. L., & Bozkurt, B. (2011). Digoxin treatment in heart failure - Unveiling risk by cluster analysis of DIG data. International Journal of Cardiology, 150(3), 264-269. https://doi.org/10.1016/j.ijcard.2010.04.021